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Abstract
Introduction:  Mucosal  leishmaniosis  (ML)  is  a  severe  clinical  form  of  leishmaniosis.  Complex
factors related  to  the  parasite  and  the  host  are  attributed  to  the  development  of  mucosal
lesions. Leishmania  RNA  virus  1  (LRV1)  can  disrupt  immune  response,  and  may  be  the  main
determinant  of  severity  of  the  disease;  it  should  be  investigated.
Objective:  To  study  the  existence  of  clinical  differences  between  patients  with  ML  with
endosymbiosis  by  LRV1  and.  those  without  it.
Methods:  A  cross-sectional  cohort  study  with  clinical  evaluation,  polymerase  chain  reaction
(PCR) detection  of  Leishmania,  species  classiﬁcation,  and  search  of  LRV1  was  performed.  Only
patients with  conﬁrmed  diagnosis  of  ML  by  positive  PCR  and  with  nasal  mucosa  injuries  were
included in  this  analysis.
Results:  Out  of  37  patients,  30  (81.1%)  were  diagnosed  with  Leishmania  braziliensis,  ﬁve  (13.5%)
with Leishmania  guyanensis,  and  two  (5.4%)  with  mixed  infection  of  L.  braziliensis  and  L.
guyanensis. LVR1  virus  was  present  in  26  (70.3%)  of  the  cases.
 Please cite this article as: Ito MM, Catanhêde LM, Katsuragawa TH, da Silva Junior CF, Aranha Camargo LM, Mattos RG, et al. Corre-
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Conclusion:  Correlation  between  clinical  phenotype  and  presence  of  LRV1  was  not  observed,
although the  frequency  of  the  virus  is  two-fold  higher  in  mucosal  lesions  than  that  found  in  the
literature  on  skin  lesions  in  the  same  geographical  area.
© 2015  Associac¸ão  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Cérvico-Facial.  Published  by
Elsevier Editora  Ltda.  All  rights  reserved.
PALAVRAS-CHAVE
Leishmaniose
mucocutânea;
Leishmaniose;
Leishmania
braziliensis;
Leishmania
guyanensis;
Leishmaniavírus
Correlac¸ão  entre  a  presenc¸a  de  Leishmania  RNA  Vírus  1  e  as  características  clínicas
da  leishmaniose  de  mucosa  nasal
Resumo
Introduc¸ão: A  leishmaniose  de  mucosa  (LM)  é  uma  forma  clínica  grave  da  leishmaniose.  Fatores
complexos  ligados  ao  parasita  e  ao  hospedeiro  são  atribuídos  ao  desenvolvimento  das  lesões
de mucosa.  Leishmania  RNA  Vírus  1  (LRV1)  pode  subverter  a  resposta  imune,  podendo  ser  o
principal  determinante  da  gravidade  da  doenc¸a  e  deve  ser  pesquisado.
Objetivo:  Estudar  a  existência  de  diferenc¸as  clínicas  entre  pacientes  portadores  de  LM  com
endosimbiose  por  LRV1  e  as  que  não  possuem.
Método:  Foi  realizado  um  estudo  de  coorte  histórica  com  corte  transversal  com  avaliac¸ão
clínica, detecc¸ão  da  Leishmania  por  técnica  de  PCR,  classiﬁcac¸ão  da  espécie  e  pesquisa  de
LRV1. Foram  incluídos  na  análise  da  pesquisa  somente  os  pacientes  com  diagnóstico  conﬁrmado
de LM  com  PCR  positivo,  com  lesão  de  mucosa  nasal.  Resultados:  Dos  37  pacientes,  30  (81,1%)
foram diagnosticados  com  L.  braziliensis,  5  (13,5%)  com  L.  guyanensis  e  2  (5,4%)  com  infecc¸ão
mista de  L.  braziliensis  e  L.  guyanensis.  O  vírus  LVR1  estava  presente  em  26  casos  (70,3%).
Conclusão:  A  correlac¸ão  entre  o  fenótipo  clínico  e  a  presenc¸a  do  LRV1  não  foi  constatada,
porém a  frequência  do  vírus  é  duas  vezes  maior  em  lesão  de  mucosa  do  que  encontrado  em
trabalho, da  mesma  região,  sobre  lesão  cutânea.
© 2015  Associac¸ão  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Cérvico-Facial.  Publicado  por
Elsevier Editora  Ltda.  Todos  os  direitos  reservados.
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eishmaniosis  is  a  neglected  tropical  disease  that  is  largely
gnored  in  the  discussion  of  important  tropical  diseases.
ontributing  to  this  neglect  are  a  complex  epidemiology,
cology,  lack  of  simple  management  tools,  and  a lack  of
ata.1 In  2010,  the  World  Health  Organization  (WHO)  esti-
ated  there  were1  19,600  cases  of  American  cutaneous
eishmaniosis  (ACL)  in  Brazil;  they  employed  a  2.8--4.6
old  underreporting  grade  that  is  considered  mild.1 Vega
t  al.  calculated  the  actual  per  capita  cost  (medical  and
on-medical  expenditure)  of  cutaneous  leishmaniosis  (CL)
reatment  in  Colombia  to  be  US$  345.  Projecting  the  same
ost  to  Brazil,  the  mean  expenditure  for  ACL  would  be  US$
,586,490  per  year  for  new  cases.  The  estimated  cost  of
ears  of  life  lost  to  disease  (DALY-WHO)  per  patient  in  Colom-
ia  was  US$  15,000.2 If  only  mucosal  leishmaniosis  (ML)  is
onsidered,  treatment  and  DALY  costs  would  be  much  higher.
Mucosal  leishmaniosis  (ML)  is  an  important  and  severe
linical  form  of  leishmaniosis,  due  to  the  destructive  poten-
ial  of  its  injuries.  ML  is  caused  by  a  protozoan  of  the
enus  Leishmania  that  features  an  extranuclear  DNA  and
 mitochondrial  organelle,  the  kinetoplast.  ML  has  two
evelopmental  forms  during  its  life  cycle:  amastigote,
hich  is  a  mandatory  intracellular  parasite  in  verte-
rates,  and  promastigote,  existing  in  invertebrate  vectors
phlebotomines).3
a
AThere  are  indications  that  leishmaniosis  may  be  native
o  the  Amazon  region.  The  Spanish  chronicler  Pedro  Pizarro
eported  that  people  living  in  hot  valleys  of  Peru  were  dec-
mated  by  a  nose  disease  on  the  Amazon  side.  The  Andean
heory,  formulated  by  Rabello,  has  its  origin  from  Peru-
ian  huacos  (pieces  of  pre-Columbian  ceramics)  discovered,
epicting  people  with  nose  deformities.  Based  on  epidemi-
logical  studies  of  Leishmania  braziliensis, Marzochi  and
arzochi  proposed  that  leishmaniosis  has  its  origin  in  the
estern  Amazon.4,5
Leishmania  are  divided  into  two  subgenera,  Viannia  and
eishmania.  In  Brazil,  at  least  seven  species  that  cause
isease  are  recognized;  cutaneous  leishmaniosis  is  caused
ainly  by  L.  (V.)  braziliensis, Leishmania  (V.)  guyanensis,
nd  L.  (L.)  amazonensis, and,  more  rarely,  by  L.  (V.)  laisoni,
.  (V.)  naifﬁ, L.  (V.)  shawi, and  L.  (V.)  lindenbergi, all  of
nterest  to  the  Amazon  region.  The  ﬁrst  three  species  are
nvolved  in  mucosal  leishmaniosis,  while  L.  (L.)  chagasi  is
he  causal  agent  of  visceral  disease.3,6--8 L.  braziliensis  is
he  main  cause  of  ML;  however,  a  recently  published  study
evealed  signiﬁcant  prevalence  of  L.  guyanensis, mainly
orth  of  the  Amazon  river.9 L.  amazonensis  may  also  cause
L.3 No  case  of  ML  by  L.  (V.)  panamensis  was  reported  in
razil.ML  can  manifest  itself  with  nasal  obstruction,  epistaxis
ssociated  with  crust  production,  rhinorrhea,  and  mild  pain.
t  the  initial  stage,  there  is  edema  and  anterior  septal
muco
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mucosa  hyperemia,  presence  of  nodules,  and  subsequent
formation  of  a  granulomatous  lesion,  which  can  evolve  to
septal  perforation,  nasal  edema  with  skin  thickening,  nasal
septum  collapse  (tapir  nose),  and  bulky  nasal  pyramid.8,10
More  than  90%  of  mucosal  injuries  affect  only  the  anterior
nasal  septum.8,9,11 This  condition  can  severely  compromise
the  nose,  palate,  gums,  pharynx,  and  larynx,  causing  defor-
mities  that  impair  phonation,  breathing,  swallowing,  and
self-esteem.8,10,11
Factors  related  to  the  parasite,  host,  and  magnitude
of  the  immune  response  are  relevant  to  mucosal  dam-
age.  Metastases  of  the  parasite  to  the  upper  aerodigestive
tract  mucosa  can  occur  through  lymphatic  or  hematoge-
nous  routes.3,8,12 The  development  of  mucosal  injuries
is  attributed  to  complex  and  poorly  understood  factors
(socioeconomic,  environmental,  and  those  of  the  host  and
parasite).  Mucosal  lesions  by  contiguity  may  also  occur.3,8
A  common  pathway  for  ML  development  is  associated
with  a  lasting  immune  response  of  the  host  against  the
parasite,  with  increases  in  inﬂammatory  mediators,  such
as  TNF-, CXCL10,  and  CCL4,  and  in  T-cell-mediated  cyto-
toxicity  activity;  higher  numbers  of  CD4+  and  CD8+  cells,
increases  in  IFN,  IL-2  and  IL-5,  lower  production  of  IL-
1013-15,  and  also  polymorphism  of  the  genes  encoding
inﬂammatory  mediators,  such  as  TNF- and  IL-6.3,13,14,15
Type  1  helper  (Th1)  T  cells  produce  lymphokines  that  acti-
vate  macrophages  (IL-2,  IFN-, TNF-, and  IL-12)  to  ﬁght
these  parasites.  Type  2  helper  (Th2)  T  cells  produce  IL-
4  and  IL-10,  which  inhibit  macrophages,  leaving  the  host
susceptible  to  infection.  Leishmania  is  able  to  facilitate
the  differentiation  of  T  cells  into  a  Th2-type  response,
characterized  by  persistent  infection.14,16,17 The  parasite
must  adapt  its  metabolism  to  the  intracellular  oxidative
stress  into  the  phagolysosome  of  macrophages.16 Paradox-
ically,  ML  is  characterized  by  an  exaggeration  in  response  to
Leishmania  antigens  and  by  a  scarcity  of  parasites.  The  exag-
geration  in  Th1  response  causes  destruction  of  soft  tissues
where  the  antigenic  particles  are  located.14,18,19
Recently,  Ives  et  al.  demonstrated  that  the  parasitism
of  Leishmania  by  the  Leishmania  RNA  virus  1  (LRV1),  a
double-stranded  RNA  virus  of  Totviridae  family,  increases  the
concentration  of  cytokines  and  chemokines  (TNF-, CXCL10,
CCL5,  IL-6)  in  TLR3/TRIF-mediated  macrophages  of  L.  guya-
nensis  clones.  In  this  study  there  was  a  high  potential  for
metastasis  in  guinea  pigs,  indicating  that  the  nucleic  acids
of  the  endosymbiotic  virus  function  as  strong  immunogens,
and  cause  destructive  mucosal  inﬂammation.13,16 Although
research  on  LRV1  has  been  conducted  since  the  original
description  of  the  virus  20  years  ago,  the  role  of  LRV1  in
leishmaniosis  remains  unknown.  No  major  studies  were  pub-
lished  on  the  impact  of  the  virus  until  the  publication  of  the
study  by  Ives  et  al.
In  the  phylogenetic  study  of  LRV,  with  the  sole  exception
of  one  strain  of  L.  major  infected  with  Leishmania  RNA  virus
2  (LRV2)  from  a  skin  lesion  in  former  Soviet  Union,  all  LRV
strains  have  their  origin  in  South  America.  In  the  assessment
of  the  genetic  evolution  among  LRV  types  and  among  Leish-
mania  species  infected  with  these  viruses,  there  is  evidence
of  a  parallelism  in  the  evolution  of  Leishmania  and  LRV.19,20
The  model  suggests  that  innate  recognition  of  LRV1
occurs  in  the  ﬁrst  hours  of  infection.  Viral  dsRNA  release
occurs  from  dead  parasites;  then  the  particle  binds  to  the
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oll-like  receptor  3  (TLR3)  and  triggers  the  inﬂammatory
ascade  that  aggravates  the  disease,  perhaps  representing
he  main  determinant  of  its  severity.21 Thus,  the  detection
f  LRV  can  have  clinical  importance,  guiding  therapy  and
rognosis.13,16,19,21
Despite  the  detection  of  LRV1  in  large  metastatic  strains
f  L.  braziliensis  and  L.  guyanensis, metastases  may  occur
n  its  absence.19,22 LRV  discovery  as  an  innate  immuno-
en,  changing  the  course  of  leishmaniosis,  should  motivate
urther  research  on  such  viral  hyperpathogens  in  other
nfections.19
The  methods  routinely  used  in  the  diagnosis  of  cuta-
eous  leishmaniosis  are  limited  for  mucosal  lesions.8,9,11,12
ontenegro’s  reaction  is  not  suitable  because  the  mucosal
njuries  typically  occur  secondary  to  cutaneous  lesions.  In
hese  lesions,  the  low  parasitaemia  signiﬁcantly  reduces  the
iagnostic  accuracy  of  biopsy,  as  well  as  the  direct  eval-
ation  with  smears  obtained  from  injuries.8,12,23 The  low
evel  of  antibodies  reduces  the  effectiveness  of  serologi-
al  tests.11,23 With  material  collected  from  mucosal  lesions,
dentiﬁcation  under  optical  microscopy  or  by  culture  rarely
s  successful.24 Polymerase  chain  reaction  (PCR)  stands  out
s  an  excellent  test  (i.e.  gold  standard),12 because  of  its
ensitivity  and  speciﬁcity,  especially  to  establish  parasite
pecies24 and  also  to  detect  LRV1.22,25
Given  the  relevant  research  on  LRV1  conducted  by  Ives13
n  the  deﬁnition  of  the  mucosal  leishmaniosis  phenotype
n  mice,  and  also  considering  also  scarcity  of  information
n  the  presence  of  this  virus  and  clinical  manifestations
n  patients,  it  was  decided  to  study  the  existence  of  clin-
cal  differences  in  patients  with  ML  with  or  without  LRV1
ndosymbiosis.  We  hope  that  this  will  contribute  to  the
ontinuing  education  process  for  health  professionals  work-
ng  with  this  very  challenging  disease,  that  still  represents
 major  public  health  problem  in  Brazil.  A  better  under-
tanding  of  this  pathology  can  guide  a  more  pragmatic  and
orkable  protocol,  in  an  attempt  to  reduce  the  destructive
ffects  of  this  disease.
ethods
he  research  was  a  cross  sectional  study  of  a  historical
ohort  of  patients  seen  at  the  otorhinolaryngology  outpa-
ient  clinic,  referred  with  suspected  ML  for  evaluation  by  a
ingle  otorhinolaryngologist  responsible  for  these  cases,  in
rder  to  obtain  a  standardization  of  clinical  information  in
 period  from  December  2012  to  December  2013.
After  conﬁrming  the  clinical  suspicion  of  ML  by  the
pecialist,  patients  were  invited  to  participate  and,  after
igning  a  written  informed  consent,  underwent  biopsy  for
istopathology  with  topical  instillation  of  10%  lidocaine
pray  into  the  lesion,  with  preservation  in  10%  buffered
ormaldehyde.  Soon  after,  material  from  the  biopsy  bed  was
ollected  with  a  cervical  brush  for  Pap  smear  to  determine
CR  in  two  samples;  to  accomplish  this,  the  surgeon  made
 slight  rotation  on  the  wound  biopsy  with  two  brushes;  one
ample  was  allocated  to  the  Leishmania  test  and  determi-
ation  of  the  species,  and  the  other  to  the  LVR1  search,
ith  preservation  in  RNALaterTM (Ambion®) until  the  time
f  DNA  and  RNA  extraction.  For  these  purposes,  commercial
its  were  used.  Patients  with  no  apparent  lesions  were  not
536  Ito  MM  et  al.
Table  1  Description  of  primers  used  for  DNA  detection  of  Leishmania.
Primer  Molecular  target
LITSR  5′-CTGGATCATTTTCCGATG-3′
L5.8S  5′-TGATACCACTTATCGCACTT-3′
Internal  Transcribed  Spacer  1  (ITS1)
kDNA F  5′-GAACGGGGTTTCTGTATGC-3′
kDNA  R  5′-TACTCCCCGACATGCCTCTG-3′
Kinetoplast  DNA  minicircle  (kDNA)
Hsp70cF 5-GGACGAGATCGAGCGCATGGT  3′
Hsp70cR  5′-TCCTTCGACGCCTCCTGGTTG-3′
Heat  shock  protein  70  (hsp70)
ORF 1 ORF 2 ORF 3
LRV F’
Capsid Protein
RNA Polymerase
Primer F’ : 5’ –
Primer R’ : 5’ –
– 3’
– 3’
Fragment of 245 pb
LRV R’
ion  of  LRV1  and  sequences  of  primers  used.
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Table  2  Staging  of  nasal  mucosa  lesions.
Stage  Clinical  observations  of  nasal  mucosa  lesion
0  No  apparent  lesions
I Nodulation  without  ulceration
II Superﬁcial  ulceration
III  Deep  ulceration
IV  Septal  perforation
V Destruction  of  nasal  architecture  and  changes
in facial  structure
t
b
1
R
T
hFigure  1  Region  ampliﬁed  for  detect
ource:  Cantanhêde.30
iopsied,  but  samples  were  collected  for  molecular  research
ith  anesthetic  instillation  (as  above),  and  again  a  brush
otation  was  made  on  the  septal  mucosa  until  a  slight  bruise
as  produced.
For  Leishmania  DNA  detection,  three  pairs  of  primers
ITS1,  kDNA,  and  hsp70)  (Table  1)  were  used;  for  LRV1,  a pair
f  primers  that  amplify  a  small  region  of  ORF1  (Fig.  1)  was
sed;  for  all  of  them,  positive  controls  were  provided.  LVR1
earch  was  performed  only  in  samples  positive  for  Leish-
ania,  since  this  is  an  intracellular  virus  of  the  parasite.
Only  patients  with  conﬁrmed  diagnosis  of  ML  with  a  pos-
tive  CPR  test  and  with  nasal  mucosal  injury  (in  order  to
et  lesion  standardization),  and  who  signed  the  free  and
nformed  consent  were  included.  Cases  not  native  to  the
razilian  North  Region  were  excluded.
To  compare  the  severity  of  lesions  associated  with  pres-
nce  of  virus,  the  staging  system  proposed  by  Lessa10 for
asal  mucosal  leishmaniosis  was  used.  Stage  0  (no  apparent
njury)  was  included  for  patients  with  latent  metastases,
ith  the  parasite  present  in  apparently  normal  mucosa
Table  2).12
Statistical  analyzes  were  conducted  with  SPSS  software
.  19,  EpiData® v.  3.1,  and  EpiData  Analysis  v.  1.1.  Descrip-
ive  analyzes  of  absolute  and  relative  frequencies  (with  a
5%  conﬁdence  interval)  for  clinical  signs  detected  and  for
pecies  of  Leishmania  were  carried  out.  Relative  risk  (RR)
f  presence  of  LRV1  in  patients  with  mucosal  vs.  skin  lesion,
btained  in  a  study  by  Catanhêde  (2011),  was  calculated.
1
i
pStaging system proposed by Lessa,10 modiﬁed by Ito.
The  collected  samples  met  the  criteria  of  Resolu-
ion  CNS  441/2011.  The  research  project  was  approved
y  the  Research  Ethics  Committee  under  No.  CAAE
0215912.1.0000.5300.
esults
his  study  evaluated  44  patients;  6  were  excluded  for  not
aving  a  diagnosis  conﬁrmed  by  PCR.  Thus,  37  patients  from
3  municipalities  of  Rondonia  and  two  of  Amazonas  were
ncluded  (Table  3  and  Fig.  2).
Twenty-nine  (78.3%)  patients  reported  having  CL  with
resence  of  a  compatible  scar  on  their  skin;  three  (8.1%)
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Table  3  Epidemiological  data  of  study  participants  in  POC,  city  of  Porto  Velho,  AC,  Brazil.
City  n  M  SCH  MA  RUR  RAct  OPL  TL  TNS
0  1  2  C  I  N
Alto  A.  Parecis  2  2  --  2  --  54.0  2  2  13.0  1  1  --  6.4
Buritis 2  2  --  2  --  51.0  2  2  24.0  1  --  1  13.0
Candeias 1  1  --  1  --  32.0  --  --  14.0  --  1  --  0.7
Costa Marques  1  1  --  --  1  24.0  --  1  13.0  1  --  --  3.0
Guajará Mirim 2  2  1  1  --  68.5  2  2  34.5  --  1  1  11.5
Humaitá 2  2  -- 1  1  35.5  1  1  25.5  1  --  1  0.5
Jaru 2  1  -- 1  1  49.0 1  1  11.0  1  --  1  11.0
Manicoré 1  1  -- -- 1  35.0 1  1  28.0  --  --  1  22.0
Nova Aripuanã  1  1  --  1  --  40.0  --  1  8.0  --  --  1  0.4
Nova Brasilândia  1  1  --  1  --  47.0  1  1  10.0  --  --  1  2.0
Ouro P.  do  Oeste  2  2  --  2  --  68.5  2  2  22.5  --  2  --  --
Porto Velho 15  13  1  12  2  54.5  6  9  13.4  5  3  7  4.5
Rio Crespo 1  1  --  1  --  58.0  --  1  --  --  --  1  10.0
São M.  Guaporé 1  -- --  1  --  72.0  1  1  10.0  1  --  --  3.0
Theobroma  3  2  -- 3  --  53.0  3  3  12.7  --  --  2  1.5
Total 37  32  2  29  6  52.4  22  28  16.6  11  8  17  5.9
n, number of participants; M, males; SCH, schooling; 0, illiterate; 1, primary education; 2, high school; MA, mean age; RUR, living in rural
area; RAct, number of individuals with rural activities; OPL, mean of onset of primary lesion in years; TL, treatment for leishmaniosis;
C, complete; I, incomplete; N, not treated; TNS, mean time of onset of nasal symptoms in years.
patients  had  a  history  of  CL  without  a  compatible  scar;  and
ﬁve  (13.5%)  patients  had  neither  previous  history  nor  CL  scar.
According  to  Table  4,  the  most  common  symptoms  were:
production  of  fetid  crusts,  chronic  fetid  rhinorrhea,  slight
epistaxis  associated  with  crust  removal,  nasal  obstruction
and,  at  the  time  of  physical  examination,  granulomatous
ulcer,  presence  of  crusts,  mucosal  hyperemia,  and  septal
perforation.
Of  this  group  of  37  patients,  30  (81.1%)  were  diagnosed
with  L.  braziliensis, ﬁve  (13.5%)  with  L.  guyanensis, and  two
(5.4%)  had  mixed  infection  with  L.  braziliensis  and  L.  guya-
nensis.  LVR1  virus  was  present  in  26  cases  (70.3%),  with  23  of
them  associated  with  L.  braziliensis, two  with  L.  guyanensis,
and  one  with  a  mixed  infection.
The  mean  time  for  onset  of  the  primary  lesion  was  16.6
years  (95%  CI  11.1--22.1;  SD  =  16.4),  ranging  from  0  to  66
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Figure  2  Main  signs  and  symptoms  presented  by  patients  eval-
uated  in  the  survey.
years.  When  the  groups  were  compared  with  respect  to  pres-
ence  or  absence  of  LRV1,  the  mean  time  for  onset  of  the
primary  lesion  was  16.2  years  (CI  95%  10.2--22.2;  SD  =  14.9)
for  LRV1+  and  17.7  years  (95%  CI  4.0--31.4;  SD  =  20.4)  for
LRV1−.  There  was  no  difference  between  LRV1+  and  LRV1−
groups  (p  =  0.790).
The  mean  time  for  the  onset  of  nasal  symptoms  was
5.9  years  (95%  CI  3.5--8.3,  SD  =  7.3),  ranging  from  0  to  22
years.  In  the  comparison  of  presence  vs.  absence  of  LRV1
virus,  the  following  mean  times  were  obtained:  LRV1+:  5.7
Table  4  Leishmania  species  and  presence  of  LRV1  virus.
Municipality  RCP  LRV1
Lb  Lg  Lb  +  Lg
Alto  Alegre  dos  Parecis  2  --  --  2
Buritis 2  --  --  2
Candeias  do  Jamari  --  --  1  --
Costa Marques  1  --  --  1
Guajará  Mirim  2  --  --  --
Humaitá  1  --  --  1
Jaru 2  --  --  2
Manicoré  2  --  --  2
Nova Brasilândia  D’Oeste 1  --  --  1
Novo Aripuanã 1  --  --  1
Ouro Preto  do  Oeste  1  1  --  --
Porto Velho  11  3  1  11
Rio Crespo  --  1  --  --
São Miguel  do  Guaporé  1  --  --  1
Theobroma  3  --  --  2
Total 30  5  2  26
Lb, Leishmania braziliensis; Lg, Leishmania guyanensis;  LRV1,
Leishmania RNA Virus 1.
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Table  5  Clinical  staging  system  for  patients’  nasal  mucosa.
Staging  Number  of  patients  LRV+  LRV−
0  1  1  0
I 5  2  3
II 4  3  1
III 14  11  3
IV 6  5  1
V 7  4  3
y
0
L
d
i
u
i
(
o
H
i
r
s
l
r
D
L
B
B
N
u
c
R
2
a
t
T
C
i
i
y
a
f
a
w
m
t
l
n
e
s
s
t
p
e
w
o
y
i
t
L
s
b
s
c
t
c
t
i
t
w
o
ﬁ
i
o
i
w
ﬁ
c
J
i
m
w
s
A
a
o
s
L
s
p
i
a
(
L
c
1
t
e
T
v
m
S
n
eTotal 37  26  11
ears  (95%  CI  2.88--8.50;  SD  =  6.95);  LRV1−: 4.7  years  (95%  CI
.04--9.43,  SD  =  6.99).  No  difference  was  observed  between
RV1+  and  LRV1− groups  (p  =  0.351).  One  patient  with  HIV
eveloped  CL  and  ML  almost  simultaneously.
To  compare  whether  patients  with  LRV1  had  more  severe
njuries  vs.  patients  without  the  virus,  lesion  staging  was
sed  in  this  analysis  (Table  5).
Table  5  shows  that  the  majority  of  the  lesions  presented
n  stages  III,  IV,  and  V  (73%).  Of  those  LRV1+  patients,  20
76.9%)  were  in  most  advanced  stages  (III,  IV,  and  V),  while
f  those  LRV− patients,  seven  (63.6%)  were  in  these  stages.
owever,  there  was  no  signiﬁcant  difference  in  clinical  stag-
ng  between  LRV1+  vs.  LRV1− patients  (p  =  0.09).
For  technical  reasons,  only  21  of  all  histopathology
esults  were  received:  six  diagnosed  with  leishmaniosis,
even  with  compatibility  (one  of  these  with  PCR  negative  for
eishmaniosis),  six  considered  nonspeciﬁc,  one  with  chronic
hinitis,  and  one  with  paracoccidioidomycosis.
iscussion
eishmaniosis  is  an  endemic  disease  in  North  Region  of
razil,  which  has  the  country’s  largest  detection  rate.9,26,27
ased  on  the  Sistema  de  Informac¸ão  de  Agravos  de
otiﬁcac¸ão  (SINAN)  database28 concerning  ACL  in  Brazil,
ntil  2003--2004,  there  was  an  increase  in  notiﬁcations  of
utaneous  leishmaniosis  (CL)  in  Brazil,  mainly  in  the  North
egion,  with  a  peak  close  to  30,000  cases/year,  but  from
006  onwards  there  has  been  a  decrease  and  stabilization  to
pproximately  21,000  notiﬁcations  per  year.  ML  follows  this
rend,  falling  from  2000  to  1400  cases  in  the  same  period.
he  state  of  Rondonia  experienced  the  steepest  decline  of
L,  decreasing  from  1981  cases  reported  in  2004  to  859  cases
n  2010.  ML  followed  a  similar  curve,  with  a  peak  of  196  cases
n  2005  that  diminished  to  118  cases  in  2010.  For  the  same
ear,  the  detection  coefﬁcients  for  CL  and  ML  were  46.33
nd  5.7  per  10,000  inhabitants,  respectively.
The  epidemiological  proﬁle  of  the  studied  group  was  as
ollows:  men  (86%)  with  a  mean  age  of  52  years,  living  in
 rural  area,  with  a  history  of  CL  for  a  mean  of  18  years,
ith  no  treatment  or  only  incompletely  treated,  and  with  a
ean  of  5.4  years  of  nasal  symptoms.  This  proﬁle  is  similar
o  that  of  Guerra’s9 study  in  Manaus  on  47  patients  with  ML;
ittle  difference  in  mean  age  (47  years)  and  in  duration  of
asal  lesion  (8.3  years)  was  observed.  In  this  study,  speciﬁc
pidemiological  proﬁles  for  LRV1+  and  LRV1− exhibited  no
igniﬁcant  difference.
The  predominant  species  in  cases  of  ML  was  L.  brazilien-
is  (81%);  corroborating  the  ﬁndings  of  Guerra9 and  contrary
m
c
cIto  MM  et  al.
o  other  published  data,  the  present  study  found  ﬁve  (13.5%)
atients  infected  with  L.  guyanensis. To  the  authors’  knowl-
dge,  this  is  the  ﬁrst  report  of  nasal  mucosa  mixed  infection
ith  L.  braziliensis  and  L.  guyanensis, with  two  (5.6%)  cases:
ne  with  the  virus,  and  both  cases  involving  palate  and  phar-
nx  mucosa.  This  ﬁnding  increased  the  rate  of  L.  guyanensis
nfections  to  19%,  conﬁrming  the  signiﬁcant  prevalence  of
his  species.  There  are  few  studies  on  the  prevalence  of
eishmania  species  in  the  region;  it  is  believed  that  this
pecies  (i.e.  L.  guyanensis) has  always  been  present,  in  part
ecause  it  was  detected  in  the  present  and  also  in  Guerra’s
tudy.
The  presence  of  mixed  infections  highlights  the  lack  of
ross-protection,  which  a  particular  species  can  elicit  rela-
ive  to  another  species.  However,  this  dual  infection  could
onstitute  a  large  source  of  antigens,  generating  a  Th1-
ype  hyperimmune  response  and  causing  a more  extensive
nvolvement  of  aerodigestive  mucosa,  a  ﬁnding  observed  in
hese  two  patients.
Of  the  37  cases,  LRV1  was  detected  in  26  (70.3%).  LRV1
as  detected  in  23/30  cases  of  L.  braziliensis, 2/5  cases
f  L.  guyanensis, and  1/2  cases  of  mixed  infections.  These
ndings  reveal  a  high  frequency  of  this  virus  in  mucosal
nfections  by  both  Leishmania  species;  however,  one-third
f  patients  had  ML  and  did  not  harbor  the  virus,  indicat-
ng  that  metastatic  lesions  exhibit  other  factors  associated
ith  this  clinical  form.  Pereira  et  al.  found  LRV1  in  two  of
ve  cases  (40%)  of  CL  from  the  North  Region  of  Brazil,  and  no
ases  with  LRV1  in  40  ACL  patients  (nine  with  ML)  in  Rio  de
aneiro  (Southeastern  Region);  Ogg25 detected  25.5%  LRV1+
n  47  samples  of  ACL  (two  of  ML).  Hartley19 reported  that  LRV
ay  contribute  variably  to  ML,  acting  in  isolation  or  together
ith  other  factors.
In  Pereira’s  study,  the  absence  of  LRV1  in  Rio  de  Janeiro
upports  theories  proposing  that  Leishmania  is  native  to  the
mazon  region,  while  the  species  that  predominate  in  South
nd  Southeast  Regions  of  this  country  may  have  different
rigins  (Mediterranean  theory).4,5 The  presence  of  LRV1  can
erve  as  phylogenetic  marker  for  the  origin  of  parasites.
eishmania  from  Amazon  region  have  higher  genetic  diver-
ity  than  Southeast  Leishmaniae.29
Cantanhêde,30 in  his  work  on  LRV1  detection  in  ACL
atients,  which  is  part  of  a  larger  research  group  on  ACL
n  the  Amazon  region  (and  of  which  the  present  work  is
lso  part),  detected  35.9%  LRV1  positivity  in  78  CL  patients
RR  =  0.63;  95%  CI  0.10--0.55).  In  the  present  assessment,
RV1  detection  in  ML  was  70.3%,  showing  a signiﬁcant  asso-
iation  of  virus  involvement  with  ML  (RR  =  2.67;  95%  CI
.82--9.81).  This  association  may  result  from  a  change  in
he  immune  response  caused  by  this  virus.13,16,19,21
For  the  ﬁrst  time,  a  correlation  study  between  pres-
nce  of  LRV1  and  clinical  phenotype  of  ML  was  carried  out.
his  study  found  no  signiﬁcant  difference  between  LRV1+
s.  LRV1-  groups  based  on  the  staging  system  proposed  for
ucosal  lesions,10 with  regard  to  the  severity  of  injuries.
imilarly,  epidemiological  differences  between  groups  were
ot  found,  nor  differences  between  signs  and  symptoms
xhibited  by  such  groups.Faced  with  the  possibility  of  using  the  virus  to  determine
ore  severe  lesions  or  lesions  with  more  rapid  onset,  and
onsidering  that  this  would  cause  the  patient  to  seek  medi-
al  care  more  quickly,  the  authors  evaluated  the  elapsed
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interval  to  the  onset  of  symptoms  of  nasal  injury  for  each
group  (LRV+/LRV−) after  the  onset  of  the  skin  injury,  and
also  the  time  spent  by  each  group  to  seek  medical  advice
after  the  onset  of  nasal  symptoms.  These  two  pieces  of  infor-
mation  could  represent  the  precocity  of  the  onset  of  the
injuries  and  the  severity  of  their  clinical  symptoms,  respec-
tively.  There  was  no  signiﬁcance  in  the  time  to  onset  of
symptoms  (p  =  0.13),  or  in  the  elapsed  time  to  seek  medical
advice  (p  =  0.35)  between  groups.
To  compare  the  degree  of  mucosal  compromise  between
the  two  groups,  staging  of  septal  injuries  was  performed,
as  proposed  by  Lessa,10 with  the  inclusion  of  stage  0  for
cases  where  the  mucosa  shows  normal  appearance,  but
contains  parasites.12 This  staging  was  done  quite  timely,
considering  that  this  study  only  included  nasal  injury,  which
comprises  more  than  90%  of  mucosal  injuries.8,9,11 Among
LRV1+  patients,  four  (15.38%)  were  in  the  most  advanced
stage;  and  among  LRV− patients,  three  (27.3%)  were  also
in  this  stage.  There  was  no  difference  in  group  staging
(p  =  0.09).
Considering  that  these  patients  visit  the  doctor  with
injuries  that  are  already  very  advanced,  these  lesions  would
probably  be  at  a  stage  where  a  differentiation  between  both
groups,  with  respect  to  clinical  phenotype,  can  no  longer
be  made.  Whether  there  are  differences  was  not  found  in
this  study;  but  undoubtedly,  it  was  ascertained  that  strongly
destructive  lesions  are  virus-independent.
In  an  ideal  scenario,  CL  patients  with  and  without  LRV1
would  be  followed-up,  so  that  one  could  compare  the  devel-
opment  of  mucosal  lesions  of  both  groups.  However,  in  daily
routine  this  appears  impractical,  because  the  appearance
of  these  lesions  can  take  a  very  long  time;  and  as  Figueroa
et  al.12 showed  in  their  study,  the  parasite  may  be  present
in  healthy  mucosa  without  indicating  disease.  These  authors
point  out  that  this  condition  is  more  the  rule  rather  than
exception.
ML  patients  are  diagnosed  late,  and  most  present  with
advanced  lesions,  with  a  great  potential  of  occurrence  of
sequel  after  treatment.  This  scenario  may  reﬂect  the  dif-
ﬁculty  of  accessing  the  medical  care  system,9,27 diagnostic
difﬁculty,8,9,11,12 and/or  poor  knowledge  of  the  disease.
It  is  common  that  in  his/her  ﬁrst  contact  with  a  patient
clinically  diagnosed  with  ML,  the  physician  (general  prac-
titioner,  dermatologist,  or  infectious  disease  specialist)  is
unfamiliar  with  clinical  evaluation  of  nasal  mucosa,  which
is  the  most  common  site  for  this  disease.  Thus,  this  profes-
sional  ends  up  referring  this  patient  to  the  otolaryngologist,
who  also  is  not  used  to  mucosal  granulomatous  diseases,  due
to  the  difﬁculty  for  conﬁrmation  of  the  diagnosis  of  this  dis-
ease.  The  diagnostic  means  available  in  health  facilities  are
insufﬁcient  and  inadequate  to  conﬁrm  an  ML  case,  due  to
natural  difﬁculties  of  the  disease  (low  parasitemia  in  lesions,
previous  skin  infection).  Thus,  one  would  depend  on  more
complex  tests  such  as  PCR  that  are  not  available  in  endemic
areas.
LRV1  exists  in  many  species  of  Leishmania, in  the  form
of  stable  infection.  The  virus  has  been  detected  through-
out  South  America  in  patients  with  cutaneous  leishmaniosis,
often  complicated  by  the  presence  of  infectious  metas-
tasis  accompanied  by  an  underlying  hyperinﬂammatory
response.13 LRV1  detection  may  represent  clinical  beneﬁts
by  guiding  treatment  and  prognosis,  due  to  its  potential  in
1sal  leishmaniosis  539
etermining  the  clinical  forms  of  leishmaniosis.  Additionally,
t  can  function  as  a target  for  development  of  new  treat-
ents,  for  example,  the  production  of  vaccines  or  other
harmacologic  agents.  LRV1  seems  not  to  be  the  last  frontier
n  elucidating  the  pathophysiology  of  ML,  but  it  represents
nother  strong  factor  involved  in  the  natural  history  of  this
isease.
onclusion
espite  the  demonstration  of  an  association  between  pres-
nce  of  LRV1  virus  and  a  change  in  immune  response,  this
tudy  found  no  correlation  among  clinical  features  and  pres-
nce  of  the  virus  in  patients  with  mucosal  leishmaniosis.
onetheless,  the  frequency  of  the  virus  in  mucosal  injuries
s  twice  that  in  skin  lesions,  demonstrating  the  need  for  a
etter  understanding.
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